Celsus Therapeutics MRX-6 Selected as One of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence

NEW YORK AND LONDON Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company MRX-6 treatment for eczema has been selected as one of the “Top 10 Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Windhover Information, of Elsevier Business Intelligence, a global leader in the field of healthcare industry information. Click here for the full press release

The release as fetched from its publisher. akaritx.com ↗